Bicara Therapeutics Inc. Common Stock (BCAX) Income Statement Analysis

See more : Marquee Raine Acquisition Corp. (MRACW) Income Statement Analysis – Financial Results

Complete financial analysis of Bicara Therapeutics Inc. Common Stock (BCAX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bicara Therapeutics Inc. Common Stock, a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Bicara Therapeutics Inc. Common Stock (BCAX)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.bicara.com

About Bicara Therapeutics Inc. Common Stock

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.

Unable to fetch income statement for: BCAX

Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

November 12, 2024globenewswire.com

On track to initiate FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC Completed upsized initial public offering, raising approximately $362 million in gross proceeds, with full exercise of the underwriters' option to purchase additional shares...

Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference

November 11, 2024globenewswire.com

BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies for patients with solid tumors, today announced that Claire Mazumdar, PhD, MBA, Chief Executive Officer of Bicara Therapeutics,...

Last Week's 3 Biotech IPOs Prompt Huge Insider Buying

September 22, 2024247wallst.com

24/7 Wall St. Insights Initial public offerings at three biotechs last week tempted insiders to make huge purchases of shares.

Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

September 16, 2024globenewswire.com

BOSTON, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies for patients with solid tumors, today announced the closing of its initial public offering of 20,125,000 shares of...

U.S. IPO Weekly Recap: 3 Biotechs Lead Active September IPO Market

September 14, 2024seekingalpha.com

Six IPOs debuted this past week, including three deals of more than $100 million. Seven IPOs submitted initial filings. Outparcel REIT FrontView REIT filed to raise $100 million, and Chinese on-demand courier service provider BingEx also filed to raise $100...

TPG-backed Bicara Therapeutics shares surge 46% in stellar market debut

September 13, 2024reuters.com

Shares of Bicara Therapeutics surged nearly 46% in their market debut on Friday, signaling strong investor interest for the TPG-backed cancer therapy developer.

Bicara Therapeutics Announces Pricing of Upsized Initial Public Offering

September 12, 2024globenewswire.com

BOSTON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the pricing of its initial public offering of 17,500,000 shares of...

Bicara Therapeutics targets $265 mln proceeds in upsized US IPO

September 11, 2024reuters.com

Bicara Therapeutics, a TPG-backed biopharmaceutical company developing a therapy targeting tumors, said on Wednesday it plans to raise up to $265 million through an upsized initial public offering (IPO) in the United States.

U.S. IPO Weekly Recap: 2 APAC Microcaps Go Public In Short Labor Day Week As The Pipeline Grows

September 7, 2024seekingalpha.com

Two small IPOs and two SPACs debuted this past week - Pheton Holdings, Powell Max, Vine Hill Capital, and Andretti Acquisition II, respectively. Eight IPOs submitted initial filings this past week, including three names that filed to raise $100 million...

Bicara Therapeutics aims for up to $828 mln valuation in U.S. IPO

September 6, 2024reuters.com

Bicara Therapeutics said on Friday it is seeking a valuation of up to $828 million in its initial public offering in the United States, as new listings continue to flock the markets.

Source: https://incomestatements.info
Category: Stock Reports

Bicara Therapeutics Inc. Common Stock (BCAX) Income Statement Analysis – Financial Results

Leave a Reply Cancel reply

Recent Posts

Categories